content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Spark Therapeutics, Inc. (ONCE)

83.07
0.85
(1.03%)
Sep 11, 4:00PM EDT
content_middle

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is based in Philadelphia, Pennsylvania.

Previous Close: 
82.22
Open: 
83.76
Bid: 
80.68
Ask: 
84.07
1yr Target Price: 
89.54
Day's Range: 
82.25 - 85.26
52wk Range: 
35.07 - 86.86
Volume: 
320579
Average Daily Volume: 
489580
Market Capitalization: 
2.60B
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
31250000M
content_right

Pages